Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 14, 2026 11:30 ET | Source: Omniscient Neurotechnology

Omniscient Secures New CPT® Code for Connectomic Analysis, Validating the Clinical Utility of Brain Network Mapping

Omniscient secures new AMA CPT® code for connectomic analysis, validating Quicktome’s clinical utility in brain care and advancing reimbursement.
January 12, 2026 09:13 ET | Source: Global Alzheimer’s Platform Foundation®

Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Spear Bio for the Transformative Bio-Hermes-002 Study

WASHINGTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive...
January 09, 2026 16:45 ET | Source: US Neurology Associates

U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care

DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates (“USNA” or...
January 07, 2026 11:02 ET | Source: Research and Markets

AI in Neurology Markets and Competition Intelligence 2025-2030: Top Companies Invest in AI-Neurology Solutions for Better Care

Dublin, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The "AI in Neurology: Global Markets" has been added to ResearchAndMarkets.com's offering. The global AI in neurology market is quickly expanding, with...
January 06, 2026 01:00 ET | Source: EG 427

EG 427’s Clinical Data Showing Sustained Incontinence Episode Reduction with EG110A DNA Therapy Maintained at 6 Months Timepoint

Paris, Jan. 06, 2026 (GLOBE NEWSWIRE) -- 88% reduction in urinary incontinence episodes in patients with neurogenic bladder sustained through 24 weeksGood tolerability maintainedEnrollment and...
December 12, 2025 10:16 ET | Source: BCC Research LLC

Brain Tumor Therapeutics Market to Grow at 11.1% CAGR Through 2030

The global market for brain tumor therapeutics was valued at $2.5 billion in 2024 and is projected to reach $4.7 billion by the end of 2030.
December 11, 2025 12:29 ET | Source: AB Science

AB Science annonce une nouvelle publication sur Medrxiv mettant en évidence le bénéfice clinique du masitinib chez les patients atteints de Sclérose Latérale Amyotrophique avant toute perte complète de fonction

COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR MEDRXIV METTANT EN ÉVIDENCE LE BÉNÉFICE CLINIQUE DU MASITINIB CHEZ LES PATIENTS ATTEINTS DE SCLÉROSE LATÉRALE AMYOTROPHIQUE AVANT...
December 11, 2025 12:29 ET | Source: AB Science

AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function

PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant...
December 10, 2025 07:30 ET | Source: Vertero Therapeutics, Inc.

Vertero Establishes Scientific Advisory Board to Advance Innovation in Neurodegenerative Diseases

Vertero appointed 5 globally recognized leaders to its Scientific Advisory Board, strengthening the company’s mission to advance innovative therapies.
December 09, 2025 09:30 ET | Source: Medical Microinstruments, Inc.

MMI Wins FDA Clearance and Completes First U.S. Clinical Use of Robotic Microsurgical Dissection Instruments with Symani

MMI today announced that it received U.S. Food and Drug Administration 510(k) clearance for its NanoWrist® Scissors and Forceps indicated for soft tissue.